BioCentury

Current Editions

Supreme Court could shut lid on Pandora’s box, shielding FDA

In deciding mifepristone case, court could safeguard FDA from judicial second-guessing

Politics, Policy & Law

Guest Commentary

Biotech 3.0: the start of a new era

Five issues the industry must face as transitions into its third act

Finance

AIM market takes a hit as C4X looks to delist

Immunology and inflammation drug discovery company expects it can raise more capital as private company

Management Tracks

Furuta to become CFO at Takeda

Plus: IDRx names Kerstein CMO and updates from Transgene, Noetik, Egle and MannKind

BioCentury ISSN 1097-7201